Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 29:13:35-46.
doi: 10.2147/JHL.S288966. eCollection 2021.

A Methodology for Mapping the Patient Journey for Noncommunicable Diseases in Low- and Middle-Income Countries

Affiliations

A Methodology for Mapping the Patient Journey for Noncommunicable Diseases in Low- and Middle-Income Countries

Tanaya Bharatan et al. J Healthc Leadersh. .

Abstract

Noncommunicable diseases (NCDs) are responsible for 71% of all worldwide mortality each year, and have an exceptionally large impact in low- and middle-income countries (LMICs). However, there is often a lack of local data from these countries to inform practice and policy improvements. Generating locally contextualized evidence base for NCDs that can help identify gaps, aid decision-making and improve patient care in LMICs needs an innovative approach. The approach used in Mapping the Patient Journey Towards Actionable Beyond the Pill Solutions (MAPS) is designed to quantitatively map different stages of the patient journey in four critical NCDs, ie, hypertension, dyslipidemia, depression, and pain (chronic and neuropathic) across selected LMICs in Africa, the Middle East, South East Asia, and Latin America. The key touchpoints along the patient journey include awareness, screening, diagnosis, treatment, adherence, and control or remission. MAPS employs an evidence mapping methodology that follows a three-step semi-systematic review: 1) systematic peer-reviewed database search; 2) unstructured searches of local or real-world data; and 3) expert opinion. Evidence generation and visualization is based on locally validated and deduplicated data published over the last 10 years. This approach will be the first to provide quantitative mapping of the different stages of the patient journey for selected NCDs in LMICs. By focusing on local, patient-centric data, the goal of the MAPS initiative is to address and prioritize local research and knowledge gaps, then contribute to evidence-based, high-quality, and affordable advances in the management of NCDs in LMICs. This will ultimately improve patient outcomes and contribute towards the achievement of global NCD targets.

Keywords: decision-making; evidence mapping; low- and middle-income countries; noncommunicable diseases; patient journey.

PubMed Disclaimer

Conflict of interest statement

No author received an honorarium for the preparation of the article. Pai-Hui Huang, Barrett Jeffers and Kannan Subramaniam are current employees of Viatris Inc and were previously employed at Upjohn Division, Pfizer Ltd. Tanaya Bharatan and Kaveri Sidhu are employees of Pfizer Ltd. Dr. Peter Lansberg has received consultancy and speaker honorarium payments from Pfizer, Amgen, and Sanofi. The remaining authors have no conflicts of interest to declare. The views and opinions expressed in this article are those of the authors. They do not represent or reflect in any way the official policy or position of their current or previous employers. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Stages of the patient journey in noncommunicable diseases.
Figure 2
Figure 2
Overall process for data collection and analysis in the MAPS methodology.
Figure 3
Figure 3
Visualization of the point estimates of patient journey stages.
Figure 4
Figure 4
Estimating the proportion and absolute numbers of at-risk population sequentially through patient journey stages. n=absolute number of at-risk populations extrapolated from proportion of patients estimated at various patient journey stages.
Figure 5
Figure 5
Sample evidence map of noncommunicable disease patient journey. *Low strength of evidence (anecdotal data and studies with non-nationally representative population, single center or sample size<500).
None

References

    1. World Health Organization. Noncommunicable diseases. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases. Accessed June15, 2020.
    1. World Health Organization. Noncommunicable diseases country profiles; 2018. Available from:https://www.who.int/publications/i/item/9789241514620. Accessed June, 2020.
    1. World Health Organization. Global action plan for the prevention and control of NCDs 2013-2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/94384/9789241506236_eng.... Accessed June10, 2020.
    1. NCD Alliance. Home page. Available from: https://ncdalliance.org. Accessed June29, 2020.
    1. Tripathy JP. Research priorities in non-communicable diseases in developing countries: time to go beyond prevalence studies. Public Health Action. 2018;8(2):98–99. doi:10.5588/pha.18.0023 - DOI - PMC - PubMed

LinkOut - more resources